A comparative study of oral and percutaneous bisoprolol

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2018
INTERVENTION: Oral bisoprolol (1.25 to 5 mg, once / day, 6 months) percutaneous bisoprolol (2 to 8 mg, once / day, 6 months) CONDITION: Hypertension PRIMARY OUTCOME: Herat rate (Holter ECG); Bood pressure(early morning, night time) INCLUSION CRITERIA: Hypertensive patient
Epistemonikos ID: 21c8dbc230136c5a3d96a0f72dc95c68e4669b8d
First added on: Aug 24, 2024